Menu Search
Equities

Neuronetics Inc

STIM:NMQ

Neuronetics Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.17
  • Today's Change0.09 / 8.33%
  • Shares traded205.80k
  • 1 Year change-19.86%
  • Beta2.3020
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Neuronetics Inc grew revenues 9.42% from 65.21m to 71.35m while net income improved from a loss of 37.16m to a smaller loss of 30.19m.
Gross margin75.91%
Net profit margin-45.06%
Operating margin-39.78%
Return on assets-32.93%
Return on equity-100.13%
Return on investment-42.47%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Neuronetics Inc fell by 10.66m. Cash Flow from Financing totalled 22.70m or 31.81% of revenues. In addition the company used 32.04m for operations while cash used for investing totalled 1.32m.
Cash flow per share-1.03
Price/Cash flow per share--
Book value per share0.6433
Tangible book value per share0.6433
More ▼

Balance sheet in USDView more

Neuronetics Inc has a Debt to Total Capital ratio of 75.51%, a lower figure than the previous year's 80.73%.
Current ratio2.58
Quick ratio2.37
Total debt/total equity3.08
Total debt/total capital0.755
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.